Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Impax Laboratories Inc (NASDAQ:IPXL)

12.05
Delayed Data
As of Jan 20
 0.00 / 0.00%
Today’s Change
11.88
Today|||52-Week Range
40.74
-9.06%
Year-to-Date
EpiPen Competitor, Auvi-Q, Will Hit the Market in February
Jan 19 / TheStreet.com - Paid Partner Content
CVS cuts cost for generic EpiPen competitor
Jan 12 / CNNMoney.com
Examining Volkswagen and Fiat Chrysler's Emissions Cheating Scandals
Jan 13 / Zacks.com - Paid Partner Content
Cigna Defends Abandoning EpiPen Coverage
Jan 11 / TheStreet.com - Paid Partner Content
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlig...
Jan 13 / Zacks.com - Paid Partner Content
Biotech Premarket Movers: IPXL, SGMO, ARLZ
Jan 11 / TheStreet.com - Paid Partner Content
Stock Market Roundup, Jan. 12: AMZN Jobs, FCAU Cheating, AKS & X Tank
Jan 12 / Zacks.com - Paid Partner Content
Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases
Jan 11 / Zacks.com - Paid Partner Content
CVS Debuts Cheap EpiPen Alternative
Jan 12 / Zacks.com - Paid Partner Content
Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit
Jan 09 / Zacks.com - Paid Partner Content